SAN RAMON, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO), today announced that the Chinese National Medical Products Administration (NMPA), which regulates medical devices and pharmaceuticals in China, has approved CooperVision MiSight® 1 day contact lenses for use within the country following a priority review.
“We are extremely excited to receive this approval,” said Al White, President and CEO. “The increasing incidence of myopia is one of the most pressing global eye-health issues we face today, and receiving approval from the NMPA allows us to work closely with eye-care professionals proactively treating children in China. MiSight® is the most innovative contact lens in the market, and we remain incredibly passionate about promoting it along with our ortho-k and SightGlass Vision® myopia management products.”
MiSight® is the first Chinese NMPA approved soft contact lens with an indication relating to slowing the progression of axial length in patients who at initiation are 8-12 years old and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. Myopia (nearsightedness or short-sightedness) progression has been linked to causing cataracts, retinal detachment, glaucoma and myopic maculopathy later in life. Within China, the prevalence of myopia among high school students is estimated to be around 80 percent. Additional information may be found at CooperVision.com and in the CooperVision MiSight® trade release.
The company will provide further information on its September 2, 2021 earnings call.
About CooperCompanies
CooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com
The New Year Introduces Continuum's Entry-Level Tier, Starting at $25,000 Per YearNEW YORK, Dec. 22,…
BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with…
CHICAGO, Dec. 22, 2025 /PRNewswire/ -- TrustCommerce®, a Sphere company and leading provider of end-to-end…
MIAMI, Dec. 22, 2025 /PRNewswire/ -- BioFlorida, Inc. ("BioFlorida"), Florida's preeminent life sciences association, is…
Andreessen Horowitz leads the funding round which will accelerate the company's leadingtelehealth marketplaceAUSTIN, Texas, Dec.…
MMJ's position is further fortified by its FDA Orphan Drug Designations for the treatment of…